DiaMedica Therapeutics Inc. DMAC

MINNEAPOLIS, September 30, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that it will host a virtual key opinion leader (KOL) event on October 23, 2026 at 8:00am Eastern Time to discuss fetal growth restriction (FGR), the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment for FGR and preli

MINNEAPOLIS, September 02, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York.

DMAC reports statistically significant blood pressure reductions in late-onset preeclampsia, progresses FGR study, and maintains cash runway through 2027 despite increased R&D spending.

Moby summary of DiaMedica Therapeutics Inc.'s Q2 2026 earnings call

MINNEAPOLIS, August 10, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2026. Management will host a conference call Tuesday, August 11, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 2026

MINNEAPOLIS, August 04, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its second quarter 2026 financial results will be released after the markets close on Monday, August 10th. DiaMedica will host a live conference call on Tuesday, August 11th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business upda

1 Main Capital, a boutique investment firm, recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. 1 Main Capital Partners returned 15.0% in Q2 2026, compared to 15.2% and 21.6% for the S&P 500 (SPX) and Russell 2000 (RTY), respectively. SPX and RTY delivered their best performance since 2026 […]

MINNEAPOLIS, July 17, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on July 15, 2026, it granted options to purchase an aggregate of 160,000 shares of DiaMedica’s common stock to a newly hired non-executive employee whose employment commenced in July 2026. The stock options were a material inducement to the employee’s acc

MINNEAPOLIS, June 23, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alfa) for the treatment of fetal growth restriction (FGR). This is the first clinical evaluation of DM199 in FGR. The open-label, single-arm study is designed

MINNEAPOLIS, June 16, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development of DM199 (rinvecalinase alfa) for the treatment of preeclampsia (PE). DiaMedica believes, based on the FDA’s feedback, that the previously completed rat reproductive toxicit